Mark Compton is the new CEO of St Luke’s Care.
Sydney based not-for-profit group St Luke’s Care has appointed Mark Compton CEO following the retirement of George Toemoe after 12 years in the role.
Mr Compton is currently the CEO of biopharmaceutical company Immune System Therapeutics and has previously held senior management roles with the Royal Flying Doctor Service and Alpha Healthcare.
“Mr Compton joins us at an exciting time for St Luke’s Care, with all operating divisions experiencing significant growth and development,” said the organisation’s chairman Julian Beaumont.
The group has recently finished work on its aged care and retirement living facilities in Little Bay.
A $22 million refurbishment of the St Luke’s Hospital in Potts Point has also been completed.
Mr Compton is a pharmacologist by profession and he began his career in research and teaching.
As Managing Director of Alpha Healthcare he controlled a group of nine hospitals and oversaw the development of Westmead Private Hospital.
Mr Beaumont paid tribute to Mr Toemoe for his contribution as CEO for over a decade.
“His commitment to furthering the success of St Luke’s Care at every opportunity has been exemplary throughout his long career as its chief executive, and he leaves the group with the board’s gratitude and best wishes,” Mr Beaumont said.
Mr Compton will take up the new position on 30 March.